Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon-Like Peptide-1 Receptor Agonists - A Review.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2024-05-17 DOI:10.2174/0115748863301925240507044637

Naina Mohamed Pakkir Maideen, Sultan Al Rashid

{"title":"Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon-Like Peptide-1 Receptor Agonists - A Review.","authors":"Naina Mohamed Pakkir Maideen, Sultan Al Rashid","doi":"10.2174/0115748863301925240507044637","DOIUrl":null,"url":null,"abstract":"<p><p>GLP-1 receptor agonists mimic the actions of GLP-1 and are used to manage type 2 diabetes and help with weight loss. In recent times, antidiabetic GLP-1 receptor agonists have been misused widely for weight loss. This review article focuses on some serious side effects of GLP-1 receptor agonists, notified by different regulatory agencies. We searched the literature in online databases such as Medline/Pubmed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of Science, Embase, and reference lists to identify publications relevant to the serious side effects associated with the use of GLP-1 receptor agonists. Various pharmacovigilance analyses and notifications from different regulatory agencies have documented the occurrence of suicidal thoughts and self-injurious behavior associated with the use of GLP-1 receptor agonists. Healthcare professionals should be aware of GLP-1 receptor agonistsassociated suicidal thoughts and self-injurious behavior. Patients should not misuse/abuse antidiabetic GLP-1 receptor agonists and should consult their physician before using any GLP-1 receptor agonists for weight loss.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863301925240507044637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

GLP-1 receptor agonists mimic the actions of GLP-1 and are used to manage type 2 diabetes and help with weight loss. In recent times, antidiabetic GLP-1 receptor agonists have been misused widely for weight loss. This review article focuses on some serious side effects of GLP-1 receptor agonists, notified by different regulatory agencies. We searched the literature in online databases such as Medline/Pubmed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of Science, Embase, and reference lists to identify publications relevant to the serious side effects associated with the use of GLP-1 receptor agonists. Various pharmacovigilance analyses and notifications from different regulatory agencies have documented the occurrence of suicidal thoughts and self-injurious behavior associated with the use of GLP-1 receptor agonists. Healthcare professionals should be aware of GLP-1 receptor agonistsassociated suicidal thoughts and self-injurious behavior. Patients should not misuse/abuse antidiabetic GLP-1 receptor agonists and should consult their physician before using any GLP-1 receptor agonists for weight loss.

查看原文本刊更多论文

与胰高血糖素样肽-1 受体激动剂有关的自杀念头和自伤行为--综述。

GLP-1 受体激动剂模仿 GLP-1 的作用，用于控制 2 型糖尿病和帮助减肥。近来，抗糖尿病 GLP-1 受体激动剂被广泛滥用于减肥。这篇综述文章重点介绍了不同监管机构通报的 GLP-1 受体激动剂的一些严重副作用。我们在 Medline/Pubmed/PMC、Google Scholar、Science Direct、Ebsco、Scopus、Web of Science、Embase 等在线数据库和参考文献列表中检索文献，以确定与使用 GLP-1 受体激动剂相关的严重副作用的相关出版物。各种药物警戒分析和来自不同监管机构的通知都记录了与使用 GLP-1 受体激动剂相关的自杀念头和自残行为。医护人员应了解与 GLP-1 受体激动剂相关的自杀念头和自残行为。患者不应误用/滥用抗糖尿病 GLP-1 受体激动剂，在使用任何 GLP-1 受体激动剂减肥之前，应咨询医生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.